Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 84

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 84
---
 at all.

Other parties who bring successful
claims against us for infringement of their IP rights may obtain injunctive or other equitable relief, which could prevent us from developing
and commercializing one or more of our drug candidates. Defense of these claims, regardless of their merits, would involve substantial
litigation expense and be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement
or misappropriation against us, we may have to pay substantial damages, including treble damages and attorneys’ fees in the case
of willful infringement, obtain one or more licenses from other parties, pay royalties or redesign our infringing drug candidates, which
may be impossible or require substantial time and monetary expenditure. In the event of an adverse result in any such litigation, or even
in the absence of litigation, we may need to obtain licenses from other parties to advance our research or allow commercialization of
our drug candidates. Any required license may not be available at all, or may not be available on commercially reasonable terms. In the
event that we are unable to obtain such a license, we would be unable to further develop and commercialize one or more of our drug candidates,
which could harm our business significantly. We may also elect to enter into license agreements in order to settle patent infringement
claims or resolve disputes prior to litigation, and any such license agreements may require us to pay royalties and other fees that could
significantly reduce our profitability for any product related to that patent and thus harm our business.

Even if resolved in our favor,
litigation or other legal proceedings relating to IP claims may cause us to incur significant expenses, and could distract our technical
personnel, management personnel, or both from their normal responsibilities. In addition, there could be public announcements of the results
of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be
negative, it could have a substantial adverse effect on the market price of Aptorum Class A ordinary shares. Such litigation or proceedings
could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing
or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings.
Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their
greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could
have a material adverse effect on our ability